Cargando…

Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer

Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Danming, Wang, Lu, Xu, Jiachen, Zhao, Jie, Bai, Hua, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618022/
https://www.ncbi.nlm.nih.gov/pubmed/37915579
http://dx.doi.org/10.3389/fimmu.2023.1265865
_version_ 1785129690863763456
author He, Danming
Wang, Lu
Xu, Jiachen
Zhao, Jie
Bai, Hua
Wang, Jie
author_facet He, Danming
Wang, Lu
Xu, Jiachen
Zhao, Jie
Bai, Hua
Wang, Jie
author_sort He, Danming
collection PubMed
description Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. Thus, combining antiangiogenic therapies might increase the effectiveness of anti-PD-1/PD-L1 antibodies. In this paper, the mechanisms of anti-angiogenic agents combined with anti-PD-1/PD-L1 antibodies are illustrated, moreover, relevant clinical studies and predictive immunotherapeutic biomarkers are summarized and analyzed, in order to provide more treatment options for NSCLC patients.
format Online
Article
Text
id pubmed-10618022
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106180222023-11-01 Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer He, Danming Wang, Lu Xu, Jiachen Zhao, Jie Bai, Hua Wang, Jie Front Immunol Immunology Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. Thus, combining antiangiogenic therapies might increase the effectiveness of anti-PD-1/PD-L1 antibodies. In this paper, the mechanisms of anti-angiogenic agents combined with anti-PD-1/PD-L1 antibodies are illustrated, moreover, relevant clinical studies and predictive immunotherapeutic biomarkers are summarized and analyzed, in order to provide more treatment options for NSCLC patients. Frontiers Media S.A. 2023-10-16 /pmc/articles/PMC10618022/ /pubmed/37915579 http://dx.doi.org/10.3389/fimmu.2023.1265865 Text en Copyright © 2023 He, Wang, Xu, Zhao, Bai and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
He, Danming
Wang, Lu
Xu, Jiachen
Zhao, Jie
Bai, Hua
Wang, Jie
Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
title Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
title_full Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
title_fullStr Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
title_full_unstemmed Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
title_short Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
title_sort research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618022/
https://www.ncbi.nlm.nih.gov/pubmed/37915579
http://dx.doi.org/10.3389/fimmu.2023.1265865
work_keys_str_mv AT hedanming researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer
AT wanglu researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer
AT xujiachen researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer
AT zhaojie researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer
AT baihua researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer
AT wangjie researchadvancesinmechanismofantiangiogenictherapycombinedwithimmunecheckpointinhibitorsfortreatmentofnonsmallcelllungcancer